Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Cardiol. Apr 26, 2026; 18(4): 118879
Published online Apr 26, 2026. doi: 10.4330/wjc.v18.i4.118879
Published online Apr 26, 2026. doi: 10.4330/wjc.v18.i4.118879
Clinical outcomes of finerenone in heart failure: A systematic review and meta-analysis
Maneeth Mylavarapu, Aneeza Jamshed, Department of Cardiology, Endeavor Health Cardio
Maneeth Mylavarapu, Aneeza Jamshed, Division of Cardiology, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, United States
Madiha Kiyani, Andrew Ndakotsu, Department of Internal Medicine, MedStar Health, Geor
Vaibhav Vats, Department of Internal Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, United States
Nithin Karnan, Department of Internal Medicine, MercyOne North Iowa Medical Center, Mason, IA 50401, United States
Elizabeth Caroline Palaparthi, Department of Internal Medicine, Prime Health Consortium-Shasta Regional Medical Center, Redding, CA 96001, United States
Mahnoor Anjum, Department of Medicine, Advent Health Tampa, Tampa, FL 33613, United States
Lakshmi Sai Meghana Kodali, Division of Preventive Cardiology, Department of Cardiology, Inova Schar Heart and Vascular, Inova Health System, Fairfax, VA 22031, United States
Fabio Enrique Parada Cabrera, Department of Cardiology, Instituto Guatemalteco de Seguridad Social, Guatemala 01001, Guatemala
Co-first authors: Maneeth Mylavarapu and Madiha Kiyani.
Author contributions: Mylavarapu M and Kiyani M has made significant contributions in terms of conceptualization, thus qualified as the co-first authors of the paper; Kodali LSM and Mylavarapu M performed data curation, visualization, and interpretation; Mylavarapu M, Kiyani M, Ndakotsu A, Vats V, Karnan N, Palaparthi EC, Anjum M, Kodali LSM, Jamshed A, and Cabrera FEP wrote, reviewed and edited the manuscript; and all authors have read and approved the final manuscript.
Conflict-of-interest statement: No conflicts of interests to disclose.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Corresponding author: Maneeth Mylavarapu, MD, Senior Researcher, Department of Cardiology, Endeavor Health Cardiovascular Institute, 2100 Pfingsten Road, Glenview, IL 60026, United States. dr.maneeth.mylavarapu@gmail.com
Received: January 13, 2026
Revised: February 14, 2026
Accepted: March 19, 2026
Published online: April 26, 2026
Processing time: 91 Days and 8.4 Hours
Revised: February 14, 2026
Accepted: March 19, 2026
Published online: April 26, 2026
Processing time: 91 Days and 8.4 Hours
Core Tip
Core Tip: Finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, has shown clear benefits in chronic kidney disease, but its specific impact on heart failure (HF) has required further synthesis. Our meta-analysis of 7457 patients reveals that finerenone significantly decreases the odds of worsening HF and enhances quality of life scores. However, potential safety signals, including hyperkalemia, suggest that while finerenone is a potent tool for managing HF, its use requires vigilant monitoring to balance clinical benefits against adverse events.